Plasma biomarkers for the differential diagnosis of dementia subtypes in clinic
pTau217 emerged as the key biomarker for AD differentiation. The smaller independent contributions of individual biomarkers to FTD classification suggest that predictive information is shared across multiple markers, with NfL having the highest contribution. Plasma biomarkers show strong potential for aiding early, non-invasive differential diagnosis of AD and FTD. Further optimization is needed for LBD/PD classification.
Authors
- Stephanie Yiallourou (ORCID: https://orcid.org/0000-0002-2433-6372)
- Tiffany F. Kautz (ORCID: https://orcid.org/0000-0001-7680-4708)
- Jeremy A. Tanner (ORCID: https://orcid.org/0000-0001-9828-1776)
- Lachlan Cribb (ORCID: https://orcid.org/0000-0001-5276-5249)
- Bernard Fongang (ORCID: https://orcid.org/0000-0002-8161-1553)
- Ashley LaRoche (ORCID: https://orcid.org/0000-0003-0197-0853)
- Matthew P. Pase (ORCID: https://orcid.org/0000-0002-4143-8485)
- Julie Parker‐Garza
- Jayandra J. Himali
- A. Campbell Sullivan
- Crystal Wiedner
- Pat Kohlfeld
- Carlos Cruchaga
- Sudha Seshadri
- Claudia L Satizabal
- Mitzi M. Gonzales
Institutions
- Cedars-Sinai Medical Center (US)
- The University of Texas at San Antonio Health Science Center (US)
- Washington University in St. Louis (US)
- Institute for Neurodegenerative Disorders (US)
- Prevent Alzheimer’s Disease 2020 (US)
- Monash University (AU)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_104637
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00